Key Points
- CFO Nelson Bunker Curnes bought 5,000 shares of Mobia Medical on June 9 at an average price of $12.79, spending a total of $63,950.
- After the purchase, Curnes directly owned 366,997 shares, valued at about $4.69 million, and the trade increased his stake by 1.38%.
- Mobia Medical’s stock was trading at $12.32, with a 12-month range of $10.19 to $14.77, and analysts currently assign it a Moderate Buy consensus rating with an average target price of $20.25.
Mobia Medical, Inc. (NASDAQ:MOBI - Get Free Report) CFO Nelson Bunker Curnes bought 5,000 shares of the firm's stock in a transaction on Tuesday, June 9th. The stock was bought at an average cost of $12.79 per share, for a total transaction of $63,950.00. Following the transaction, the chief financial officer directly owned 366,997 shares of the company's stock, valued at $4,693,891.63. The trade was a 1.38% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Mobia Medical Stock Performance
NASDAQ MOBI opened at $12.32 on Friday. Mobia Medical, Inc. has a 12 month low of $10.19 and a 12 month high of $14.77. The stock has a market capitalization of $409.63 million, a price-to-earnings ratio of 66.00 and a beta of 2.84.
Mobia Medical (NASDAQ:MOBI - Get Free Report) last posted its earnings results on Thursday, June 4th. The company reported $999.00 EPS for the quarter. The company had revenue of $12.07 million during the quarter.
Analyst Upgrades and Downgrades
A number of research firms recently weighed in on MOBI. Wolfe Research began coverage on shares of Mobia Medical in a research note on Tuesday, June 2nd. They set an "outperform" rating on the stock. Wall Street Zen lowered shares of Mobia Medical from a "hold" rating to a "sell" rating in a research note on Saturday, June 6th. The Goldman Sachs Group assumed coverage on shares of Mobia Medical in a research note on Tuesday, June 2nd. They set a "buy" rating and a $31.00 target price on the stock. BTIG Research assumed coverage on shares of Mobia Medical in a research note on Tuesday, June 2nd. They issued a "buy" rating and a $19.00 price target on the stock. Finally, Zacks Research upgraded shares of Mobia Medical to a "hold" rating in a research note on Wednesday, June 3rd. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $20.25.
View Our Latest Analysis on MOBI
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
